MedTrace Logo

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

NCT02643459 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2021-03-09

Study results available
· View outcomes & findings →

Summary

Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms is supplemented with a prognostic biomarker?

Conditions

  • Triage
  • Risk Stratification With Biomarker

Interventions

BEHAVIORAL

suPAR measurement

The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Kasper K Iversen, MD, DMSci · Department of Cardiology, Herlev Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-04-06
Completion
2017-04-06

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643459 on ClinicalTrials.gov